MCID: CLN015
MIFTS: 63

Colon Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colon Adenocarcinoma

MalaCards integrated aliases for Colon Adenocarcinoma:

Name: Colon Adenocarcinoma 12 54 15 17
Adenocarcinoma of the Colon 12 6
Adenocarcinoma of Colon 12 71
Colonic Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:234
NCIt 49 C4349
UMLS 71 C0338106

Summaries for Colon Adenocarcinoma

Disease Ontology : 12 A colon carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colon Adenocarcinoma, also known as adenocarcinoma of the colon, is related to adenocarcinoma and intrahepatic cholangiocarcinoma. An important gene associated with Colon Adenocarcinoma is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs tannic acid and Zinc have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lung, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and cellular

Wikipedia : 74 Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development... more...

Related Diseases for Colon Adenocarcinoma

Diseases related to Colon Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 538)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.2 PTGS2 MSH6 MLH1 KRT20 CTNNB1 CEACAM5
2 intrahepatic cholangiocarcinoma 31.4 KRT20 CTNNB1 CDH1 APC
3 mucinous adenocarcinoma 31.4 MLH1 KRT20 CEACAM5
4 cholangiocarcinoma 31.3 PTGS2 KRT20 CTNNB1 CEACAM5 CDH1 APC
5 appendix adenocarcinoma 31.3 KRT20 CEACAM5
6 gastrointestinal stromal tumor 31.3 PTGS2 CDH1 CASP8 CASP3 ABCB1
7 gastrointestinal carcinoma 31.2 TYMS KRT20 CEACAM5 ABCB1
8 lung cancer susceptibility 3 31.2 PTGS2 KRT20 CTNNB1 CEACAM5 CDH1 CASP8
9 colorectal adenocarcinoma 31.2 TYMS PTGS2 MSH6 MLH1 KRT20 CTNNB1
10 adenoma 31.2 PTGS2 ODC1 MSH6 MLH1 CTNNB1 CDH1
11 villous adenoma 31.1 MLH1 KRT20 CEACAM5 APC
12 glioblastoma multiforme 31.0 PTGS2 ODC1 MLH1 FUT4 CTNNB1 CDH1
13 pseudomyxoma peritonei 31.0 KRT20 CTNNB1 CEACAM5 CDH1
14 tubular adenocarcinoma 31.0 KRT20 CTNNB1 CEACAM5 CDH1
15 signet ring cell adenocarcinoma 31.0 MLH1 KRT20 CEACAM5 CDH1
16 mesothelioma, malignant 31.0 TYMS KRT20 CTNNB1 CEACAM5 CDH1
17 colorectal adenoma 31.0 PTGS2 ODC1 MLH1 CTNNB1 CDH1 APC
18 neuroendocrine carcinoma 31.0 KRT20 CEACAM5 CDH1
19 breast adenocarcinoma 30.9 ODC1 CASP8 BAX ABCB1
20 myeloma, multiple 30.9 CTNNB1 CDH1 CASP8 CASP3 ABCB1
21 pancreatic adenocarcinoma 30.9 PTGS2 MLH1 CTNNB1 CDH1 CASP8 CASP3
22 esophageal cancer 30.9 TYMS PTGS2 MLH1 CTNNB1 CEACAM5 CDH1
23 ulcerative colitis 30.8 MSH6 MLH1 CTNNB1 ABCB1
24 bladder urothelial carcinoma 30.8 MLH1 KRT20 CTNNB1 CDH1 CASP3 BAX
25 goblet cell carcinoid 30.8 KRT20 CTNNB1 CDH1
26 pancreatic cancer 30.8 TYMS PTGS2 MLH1 KRT20 CTNNB1 CEACAM5
27 skin carcinoma 30.8 PTGS2 ODC1 KRT20 CDH1 CASP3
28 sarcoma 30.8 PTGS2 CTNNB1 CASP8 CASP3 ABCB1
29 transverse colon cancer 30.8 MLH1 KRT20 CEACAM5
30 cervical adenocarcinoma 30.8 PTGS2 KRT20 CEACAM5 CASP3
31 transitional cell carcinoma 30.8 PTGS2 MLH1 KRT20 CDH1
32 colitis 30.8 PTGS2 MSH6 MLH1 CTNNB1 ABCB1
33 gastric adenocarcinoma 30.8 TYMS PTGS2 ODC1 MLH1 KRT20 CTNNB1
34 squamous cell carcinoma 30.8 PTGS2 CTNNB1 CEACAM5 CDH1 CASP3
35 ovarian serous cystadenocarcinoma 30.8 CTNNB1 CEACAM5 CDH1 BAX
36 ascending colon cancer 30.8 MLH1 CEACAM5
37 familial adenomatous polyposis 30.8 PTGS2 ODC1 MSH6 MLH1 CTNNB1 CDH1
38 teratoma 30.7 KRT20 CTNNB1 CEACAM5 CDH1
39 ovary adenocarcinoma 30.7 MLH1 KRT20 CTNNB1 CEACAM5 CDH1 CASP3
40 mucositis 30.7 TYMS CASP3 ABCB1
41 bladder cancer 30.7 TYMS PTGS2 MLH1 KRT20 CDH1 CASP8
42 lymphoma, non-hodgkin, familial 30.7 RAD54L FUT4 CASP8 CASP3 BAX APC
43 leukemia, acute lymphoblastic 30.7 TYMS CASP8 CASP3 BAX ABCB1
44 neuroblastoma 30.7 PTGS2 ODC1 CTNNB1 CDH1 CASP8 CASP3
45 leukemia, acute myeloid 30.7 FUT4 CTNNB1 CDH1 CASP8 CASP3 ABCB1
46 hematologic cancer 30.7 MLH1 CASP3 BAX APC ABCB1
47 rectum adenocarcinoma 30.6 MSH6 MLH1 KRT20 CEACAM5
48 colorectal cancer 30.6 TYMS ST6GAL1 SNHG6 PTGS2 ODC1 MSH6
49 acute promyelocytic leukemia 30.6 FUT4 CASP8 CASP3 BAX ABCB1
50 lymphoma 30.6 MSH6 CDH1 CASP8 CASP3 BAX ABCB1

Graphical network of the top 20 diseases related to Colon Adenocarcinoma:



Diseases related to Colon Adenocarcinoma

Symptoms & Phenotypes for Colon Adenocarcinoma

GenomeRNAi Phenotypes related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.1 BAX CASP8 MLH1 MSH6 RAD54L TYMS

MGI Mouse Phenotypes related to Colon Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 APC BAX CASP3 CASP8 CDH1 CTNNB1
2 hematopoietic system MP:0005397 10.13 ABCB1 ACSL4 APC BAX CASP3 CASP8
3 endocrine/exocrine gland MP:0005379 10.1 ABCB1 ACSL4 APC BAX CASP3 CASP8
4 immune system MP:0005387 10.07 ABCB1 APC BAX CASP3 CASP8 CDH1
5 digestive/alimentary MP:0005381 10.03 ABCB1 APC CASP3 CDH1 CTNNB1 MLH1
6 mortality/aging MP:0010768 9.97 ABCB1 ACSL4 APC BAX CASP3 CASP8
7 hearing/vestibular/ear MP:0005377 9.85 ABCB1 ACSL4 APC BAX CASP3 CTNNB1
8 neoplasm MP:0002006 9.56 APC BAX CASP8 CDH1 CTNNB1 MLH1
9 reproductive system MP:0005389 9.28 ABCB1 ACSL4 APC BAX CASP3 CDH1

Drugs & Therapeutics for Colon Adenocarcinoma

Drugs for Colon Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4 insulin Phase 4
5 Hypoglycemic Agents Phase 4
6 Insulin, Globin Zinc Phase 4
7
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
8
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
9
Bevacizumab Approved, Investigational Phase 3 216974-75-3
10
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
11
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
12
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
13
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
14
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
15
leucovorin Approved Phase 3 58-05-9 6006 143
16
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
17
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
18
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
19
Dalteparin Approved Phase 3 9005-49-6
20
Sunitinib Approved, Investigational Phase 2, Phase 3 341031-54-7, 557795-19-4 5329102
21
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
22
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 6857599 43805
23
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
24
Panitumumab Approved, Investigational Phase 2, Phase 3 339177-26-3 50070211
25
Fluorouracil Approved Phase 3 51-21-8 3385
26
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
27
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
28
Promethazine Approved, Investigational Phase 3 60-87-7 4927
29
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
30
Floxuridine Approved Phase 3 50-91-9 5790
31
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
32
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
34 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
35
Vatalanib Investigational Phase 3 212141-54-3 151194
36
Eniluracil Investigational Phase 3 59989-18-3
37 Dermatologic Agents Phase 3
38 Cyclosporins Phase 3
39 Antifungal Agents Phase 3
40 Calcineurin Inhibitors Phase 3
41 topoisomerase I inhibitors Phase 2, Phase 3
42 Topoisomerase Inhibitors Phase 2, Phase 3
43 Angiogenesis Inhibitors Phase 2, Phase 3
44 Semaxinib Phase 3
45 Mitomycins Phase 3
46
Liposomal doxorubicin Phase 3 31703
47
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
48 Central Nervous System Depressants Phase 3
49 Anti-Arrhythmia Agents Phase 3
50 Tocolytic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 269)
# Name Status NCT ID Phase Drugs
1 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Not yet recruiting NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
2 A RANDOMISED TRIAL OF INTRAVENOUS VERSUS INTRAHEPATIC ARTERIAL 5-FU AND LEUCOVORIN FOR COLORECTAL LIVER METASTASES Unknown status NCT00002692 Phase 3 fluorouracil;isolated perfusion;leucovorin calcium
3 Multicentre Phase III Comparing To Therapeutic Sequence: Folfiri Following of Folfox6 (Group A) and Folfox6 Following Of (Group B) For Metastatic Colorectal Cancer Unknown status NCT00003260 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
4 CHEMOTHERAPY CHOICES IN ADVANCED COLORECTAL CANCER: A RANDOMISED TRIAL COMPARING 2 DURATIONS AND 3 SYSTEMIC CHEMOTHERAPY REGIMENS IN THE PALLIATIVE TREATMENT OF ADVANCED COLORECTAL CANCER Unknown status NCT00002893 Phase 3 fluorouracil;leucovorin calcium;raltitrexed
5 A Multicenter, Open-Label, Randomized, Three-Arm Study Of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) Or Oxaliplatin Or A Combination Of (5-Fu) LV + Oxaliplatin As Second-Line Treatment Of Metastatic Colorectal Carcinoma Unknown status NCT00008281 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
6 Phase III Study of An Optimized LV-5FU-Oxaliplatin Regimen in Metastatic Colorectal Cancer. C99-1. Unknown status NCT00006468 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
7 Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
8 Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2 Unknown status NCT00274872 Phase 2, Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
9 Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed Unknown status NCT00070213 Phase 3 FOLFOX regimen;capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
10 A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer Unknown status NCT00021281 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;semaxanib
11 A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)] Unknown status NCT00389870 Phase 3 cyclosporine;irinotecan hydrochloride
12 A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum Unknown status NCT00265850 Phase 3 FOLFOX or;FOLFIRI
13 Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors Unknown status NCT00091312 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
14 Phase III Randomized Study of Intensive Adjuvant Chemotherapy for Resected Colon Cancer at High Risk of Recurrence Unknown status NCT00005979 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
15 5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03). Unknown status NCT00046995 Phase 3 carboplatin;fluorouracil;leucovorin calcium
16 A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer Unknown status NCT00958737 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin;XELOX regimen;Capecitabine
17 A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Metastatic Colorectal Cancer (COIN) Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
18 A Prospective Randomised Open Label Trial of Oxaliplatin/Fluoropyrimidine Versus Oxaliplatin/Fluoropyrimidine Plus Cetuximab Pre and Post Operatively in Patients With Resectable Colorectal Liver Metastasis Requiring Chemotherapy Unknown status NCT00482222 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
19 CPT-11 in Combination With Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Relative to Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Alone in Patients With Advanced Colorectal Cancer Completed NCT00004885 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
20 Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11 Completed NCT00006103 Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium
21 PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER Completed NCT00002716 Phase 3 dexamethasone;floxuridine;fluorouracil;leucovorin calcium
22 Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer Completed NCT00392899 Phase 3 UFT adjuvant chemotherapy
23 A Randomized Phase I/III Study Of Systematic Chemotherapy With Or Without Hepatic Chemoembolization For Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum Completed NCT00023868 Phase 3 FOLFIRI regimen;cisplatin;doxorubicin hydrochloride;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C
24 A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum Completed NCT00003594 Phase 3 irinotecan;fluorouracil;leucovorin calcium;oxaliplatin
25 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
26 Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2 Completed NCT00265824 Phase 3 bevacizumab;bevacizumab, erlotinib
27 Multicenter Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone As Adjuvant Treatment Of Stage III Colon Cancer Completed NCT00026273 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
28 First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial Completed NCT00003287 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
29 Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer Completed NCT00064181 Phase 3 FOLFIRI regimen;capecitabine;celecoxib;fluorouracil;irinotecan hydrochloride;leucovorin calcium
30 A Randomized, Prospective Study Comparing Three Regimens Of Eloxatin ™ Plus Fluoropyrimidine For Evaluation Of Safety And Tolerability In First Line Treatment Of Patients With Advanced Colorectal Cancer (Tree Study) Completed NCT00062426 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
31 Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer Completed NCT00008060 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
32 A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
33 A Clinical Trial to Evaluate the Postoperative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients With Resectable Adenocarcinoma of the Colon Completed NCT00427310 Phase 3 fluorouracil;sodium heparin
34 A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo Completed NCT00056459 Phase 3 Vatalanib
35 A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum Completed NCT00056446 Phase 3 Vatalanib
36 Pan-European Trials in Adjuvant Colon Cancer (PETACC-2): Randomized Phase III Intergroup Trial of High-Dose Infusional 5-FU (+ or - Folinic Acid) Versus Standard Bolus 5-FU/Folinic Acid Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
37 Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Study of Adjuvant Therapy With Celecoxib in Combination With Chemotherapy in Patients With Curatively Resected Stage III Colon Cancer Completed NCT00085163 Phase 3 celecoxib;fluorouracil;leucovorin calcium
38 A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon Completed NCT00378716 Phase 3 5-fluorouracil;leucovorin calcium;tegafur;uracil
39 Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5-FU Plus Eniluracil to Protracted Intravenous Infusion in Previously Untreated Patients With Advanced Colorectal Cancer Completed NCT00003873 Phase 3 fluorouracil;eniluracil
40 A PHASE III PROSPECTIVE RANDOMIZED TRIAL COMPARING LAPAROSCOPIC-ASSISTED COLECTOMY VERSUS OPEN COLECTOMY FOR COLON CANCER Completed NCT00002575 Phase 3
41 Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for Stage III Colon Cancer , and Investigate Predictive Factors Based on Gene Expression Completed NCT00660894 Phase 3 folinate calcium;tegafur-uracil;tegafur-gimeracil-oteracil potassium
42 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI) Completed NCT00911170 Phase 3 Pegfilgrastim;Placebo;Standard Chemotherapy
43 Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer Completed NCT00025337 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
44 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
45 A Randomized, Open-Label, Multicenter Phase III Study of 5-FU/Leucovorin With or Without Concomitant SU5416 in Patients With Metastatic Colorectal Cancer Completed NCT00004252 Phase 3 fluorouracil;leucovorin calcium;semaxanib
46 Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer Completed NCT00003835 Phase 3 leucovorin calcium;fluorouracil;irinotecan hydrochloride
47 Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer Completed NCT00303771 Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium
48 A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity Completed NCT00316914 Phase 3 calcium gluconate;magnesium sulfate
49 A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon Completed NCT00096278 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
50 Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX Completed NCT00268398 Phase 3 oxaliplatin, folinic acid, fluorouracil;oxaliplatin, irinotecan, folinic acid, fluorouracil

Search NIH Clinical Center for Colon Adenocarcinoma

Genetic Tests for Colon Adenocarcinoma

Anatomical Context for Colon Adenocarcinoma

MalaCards organs/tissues related to Colon Adenocarcinoma:

40
Colon, Liver, Lung, Lymph Node, Breast, T Cells, Testes

Publications for Colon Adenocarcinoma

Articles related to Colon Adenocarcinoma:

(show top 50) (show all 5402)
# Title Authors PMID Year
1
Mutations in the RAD54 recombination gene in primary cancers. 6
10362365 1999
2
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. 54 61
20107900 2010
3
TAF4b and Jun/activating protein-1 collaborate to regulate the expression of integrin alpha6 and cancer cell migration properties. 54 61
20353996 2010
4
Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter. 54 61
20199127 2010
5
Extracellular ATP activates MAP kinase cascades through a P2Y purinergic receptor in the human intestinal Caco-2 cell line. 54 61
19836435 2009
6
Differences in TRAIL-induced changes of Mcl-1 expression among distinct human colon epithelial cell lines. 54 61
19782681 2009
7
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. 54 61
19881948 2009
8
Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells. 54 61
19794924 2009
9
Chemopreventive effects of polysaccharides extract from Asterina pectinifera on HT-29 human colon adenocarcinoma cells. 54 61
19470241 2009
10
No functional and transductional significance of specific neuropilin 1 siRNA inhibition in colon carcinoma cell lines lacking VEGF receptor 2. 54 61
19360289 2009
11
Soy isoflavones modulate azoxymethane-induced rat colon carcinogenesis exposed pre- and postnatally and inhibit growth of DLD-1 human colon adenocarcinoma cells by increasing the expression of estrogen receptor-beta. 54 61
19141699 2009
12
Sodium butyrate sensitizes human colon adenocarcinoma COLO 205 cells to both intrinsic and TNF-alpha-dependent extrinsic apoptosis. 54 61
19130237 2009
13
Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc. 54 61
18444242 2008
14
Human caspase-3 inhibition by Z-tLeu-Asp-H: tLeu(P2) counterbalances Asp(P4) and Glu(P3) specific inhibitor truncation. 54 61
18854175 2008
15
ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. 54 61
19014651 2008
16
Resveratrol directly targets COX-2 to inhibit carcinogenesis. 54 61
18381589 2008
17
Smad7 induces hepatic metastasis in colorectal cancer. 54 61
18781153 2008
18
Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase. 54 61
18541673 2008
19
Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. 54 61
18332086 2008
20
Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies. 54 61
18457384 2008
21
Cysteine 62 of Bax is critical for its conformational activation and its proapoptotic activity in response to H2O2-induced apoptosis. 54 61
18344566 2008
22
The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. 54 61
18855679 2008
23
Bap29varP, a variant of Bap29, influences the cell surface expression of the human P-glycoprotein. 54 61
18097552 2008
24
Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer. 54 61
17942908 2007
25
Necrosis predominates in the cell death of human colon adenocarcinoma HT-29 cells treated under variable conditions of photodynamic therapy with hypericin. 54 61
17609769 2007
26
Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. 54 61
17541169 2007
27
Site-specific bidirectional efflux of 2,4-dinitrophenyl-S-glutathione, a substrate of multidrug resistance-associated proteins, in rat intestine and Caco-2 cells. 54 61
17430634 2007
28
Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase. 54 61
17235292 2007
29
Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells. 54 61
17340576 2007
30
Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells. 54 61
16909108 2007
31
NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. 54 61
16506021 2007
32
Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. 54 61
17727795 2007
33
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. 54 61
17311703 2007
34
Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. 54 61
17106246 2006
35
Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. 54 61
17085643 2006
36
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. 54 61
16458424 2006
37
[Inhibition of cell proliferation and C-myc cancer protein expression in human colon adenocarcinoma cell line HT29 with VIP-131I-ASON]. 54 61
17121362 2006
38
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. 54 61
16568206 2006
39
Neurotensin receptors in adeno- and squamous cell carcinoma. 54 61
17094477 2006
40
Pre-treatment of HT-29 cells with 5-LOX inhibitor (MK-886) induces changes in cell cycle and increases apoptosis after photodynamic therapy with hypericin. 54 61
16545574 2006
41
Concomitant cell growth and differentiation are dependent on erbB1 and integrin activation in an autonomously surviving colon adenocarcinoma: involvement of autocrine amphiregulin secretion. 54 61
16886596 2006
42
Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. 54 61
16854083 2006
43
Role of Smad proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells. 54 61
16288847 2006
44
In-vivo imaging of tumor associated urokinase-type plasminogen activator activity. 54 61
16822063 2006
45
9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma. 54 61
16487928 2006
46
An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients. 54 61
15937692 2006
47
Molokhia (Corchorus olitorius L.) extract suppresses transformation of the aryl hydrocarbon receptor induced by dioxins. 54 61
16115717 2006
48
Sphingosine kinase 1 is up-regulated in colon carcinogenesis. 54 61
16319132 2006
49
Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. 54 61
15922743 2005
50
Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. 54 61
15930282 2005

Variations for Colon Adenocarcinoma

ClinVar genetic disease variations for Colon Adenocarcinoma:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.3922_3926AAAGA[1] (p.Glu1309fs)short repeat Pathogenic 816 rs121913224 5:112175212-112175216 5:112839515-112839519
2 RAD54L NM_003579.4(RAD54L):c.188C>A (p.Pro63His)SNV Pathogenic 6191 rs121908688 1:46715769-46715769 1:46250097-46250097
3 MSH6 NM_000179.2(MSH6):c.1808dup (p.Glu604fs)duplication Pathogenic 560013 rs1553413200 2:48026927-48026928 2:47799788-47799789
4 APC NM_000038.6(APC):c.7832C>T (p.Thr2611Ile)SNV Uncertain significance 133523 rs587778037 5:112179123-112179123 5:112843426-112843426
5 APC NM_000038.6(APC):c.1463T>C (p.Leu488Pro)SNV Uncertain significance 559962 rs368434773 5:112162859-112162859 5:112827162-112827162

Cosmic variations for Colon Adenocarcinoma:

9 (show top 50) (show all 33543)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97280902 ZZZ3 large intestine,colon,carcinoma,NS c.1366C>T p.P456S 1:77631989-77631989 3
2 COSM88263736 ZRSR2 large intestine,colon,carcinoma,NS c.553G>T p.D185Y 23:15809314-15809314 3
3 COSM88261539 ZRSR2 large intestine,colon,carcinoma,NS c.917G>A p.R306Q 23:15820296-15820296 3
4 COSM95950816 ZNHIT6 large intestine,colon,carcinoma,NS c.1364T>A p.L455H 1:85657855-85657855 3
5 COSM86861594 ZNHIT1 large intestine,colon,carcinoma,NS c.400C>T p.R134W 7:101223799-101223799 3
6 COSM98771566 ZNF813 large intestine,colon,carcinoma,NS c.1639G>A p.G547R 19:53491871-53491871 3
7 COSM91871130 ZNF536 large intestine,colon,carcinoma,NS c.1158G>T p.W386C 19:30444720-30444720 3
8 COSM91870713 ZNF536 large intestine,colon,carcinoma,NS c.2533C>G p.L845V 19:30548152-30548152 3
9 COSM94777824 ZNF521 large intestine,colon,carcinoma,NS c.3524C>T p.T1175M 18:25224394-25224394 3
10 COSM94774956 ZNF521 large intestine,rectum,carcinoma,NS c.799G>C p.E267Q 18:25227119-25227119 3
11 COSM86916483 ZNF280D large intestine,colon,carcinoma,NS c.2020A>C p.R674= 15:56658461-56658461 3
12 COSM95251466 ZNF217 large intestine,colon,carcinoma,NS c.967G>A p.D323N 20:53581860-53581860 3
13 COSM105811781 ZNF155 large intestine,colon,carcinoma,NS c.1454A>G p.H485R 19:43997278-43997278 3
14 COSM89535029 ZMIZ2 large intestine,colon,carcinoma,NS c.1850G>A p.R617H 7:44763403-44763403 3
15 COSM127394330 ZFHX4 large intestine,rectum,carcinoma,NS c.8291C>T p.P2764L 8:76855212-76855212 3
16 COSM127388315 ZFHX4 large intestine,colon,carcinoma,NS c.681C>A p.F227L 8:76704769-76704769 3
17 COSM149275347 ZFHX3 large intestine,colon,carcinoma,NS c.7928G>A p.R2643H 16:72794754-72794754 3
18 COSM149294291 ZFHX3 large intestine,colon,carcinoma,NS c.392G>T p.G131V 16:72959754-72959754 3
19 COSM149316595 ZFHX3 large intestine,rectum,carcinoma,NS c.4628G>A p.R1543H 16:72798054-72798054 3
20 COSM149297634 ZFHX3 large intestine,colon,carcinoma,NS c.9227T>G p.M3076R 16:72793455-72793455 3
21 COSM149331878 ZFHX3 large intestine,colon,carcinoma,NS c.2548C>A p.L850I 16:72957598-72957598 3
22 COSM149281001 ZFHX3 large intestine,colon,carcinoma,NS c.7490C>T p.S2497L 16:72795192-72795192 3
23 COSM149281007 ZFHX3 large intestine,colon,carcinoma,NS c.2324C>T p.A775V 16:72957822-72957822 3
24 COSM149295261 ZFHX3 large intestine,rectum,carcinoma,NS c.7279G>A p.D2427N 16:72795403-72795403 3
25 COSM149287754 ZFHX3 large intestine,rectum,carcinoma,NS c.6692C>T p.P2231L 16:72795990-72795990 3
26 COSM149281665 ZFHX3 large intestine,colon,carcinoma,NS c.8968G>A p.V2990I 16:72793714-72793714 3
27 COSM149303003 ZFHX3 large intestine,colon,carcinoma,NS c.4251G>C p.Q1417H 16:72798431-72798431 3
28 COSM149332863 ZFHX3 large intestine,colon,carcinoma,NS c.10415C>T p.A3472V 16:72787861-72787861 3
29 COSM149262764 ZFHX3 large intestine,colon,carcinoma,NS c.1532C>A p.P511H 16:72958614-72958614 3
30 COSM149309557 ZFHX3 large intestine,colon,carcinoma,NS c.7804A>G p.T2602A 16:72794878-72794878 3
31 COSM149331841 ZFHX3 large intestine,colon,carcinoma,NS c.4242A>C p.E1414D 16:72798440-72798440 3
32 COSM149309565 ZFHX3 large intestine,colon,carcinoma,NS c.7666G>A p.A2556T 16:72795016-72795016 3
33 COSM149283939 ZFHX3 large intestine,colon,carcinoma,NS c.10346C>T p.A3449V 16:72787930-72787930 3
34 COSM149331838 ZFHX3 large intestine,colon,carcinoma,NS c.9997C>A p.Q3333K 16:72788279-72788279 3
35 COSM149288753 ZFHX3 large intestine,colon,carcinoma,NS c.2339C>T p.A780V 16:72957807-72957807 3
36 COSM149286811 ZFHX3 large intestine,rectum,carcinoma,NS c.2875G>A p.D959N 16:72950810-72950810 3
37 COSM149314781 ZFHX3 large intestine,colon,carcinoma,NS c.3863C>T p.T1288M 16:72811578-72811578 3
38 COSM149321671 ZFHX3 large intestine,colon,carcinoma,NS c.3412A>T p.I1138F 16:72889767-72889767 3
39 COSM149288742 ZFHX3 large intestine,rectum,carcinoma,NS c.10831C>A p.H3611N 16:72787445-72787445 3
40 COSM149307391 ZFHX3 large intestine,colon,carcinoma,NS c.1238C>A p.T413N 16:72958908-72958908 3
41 COSM149310951 ZFHX3 large intestine,colon,carcinoma,NS c.9467G>A p.S3156N 16:72788809-72788809 3
42 COSM149267318 ZFHX3 large intestine,colon,carcinoma,NS c.3367C>T p.R1123W 16:72889812-72889812 3
43 COSM149286804 ZFHX3 large intestine,rectum,carcinoma,NS c.8360C>A p.P2787H 16:72794322-72794322 3
44 COSM149292048 ZFHX3 large intestine,colon,carcinoma,NS c.10754C>G p.S3585C 16:72787522-72787522 3
45 COSM149316603 ZFHX3 large intestine,rectum,carcinoma,NS c.4309A>G p.S1437G 16:72798373-72798373 3
46 COSM149276729 ZFHX3 large intestine,colon,carcinoma,NS c.3829G>A p.V1277M 16:72811612-72811612 3
47 COSM149309571 ZFHX3 large intestine,colon,carcinoma,NS c.7381G>A p.E2461K 16:72795301-72795301 3
48 COSM149289422 ZFHX3 large intestine,colon,carcinoma,NS c.5555A>C p.Q1852P 16:72797127-72797127 3
49 COSM149316587 ZFHX3 large intestine,rectum,carcinoma,NS c.8875A>G p.K2959E 16:72793807-72793807 3
50 COSM149267991 ZFHX3 large intestine,colon,carcinoma,NS c.6296C>T p.P2099L 16:72796386-72796386 3

Expression for Colon Adenocarcinoma

Search GEO for disease gene expression data for Colon Adenocarcinoma.

Pathways for Colon Adenocarcinoma

Pathways related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 PTGS2 CTNNB1 CASP8 CASP3 BAX APC
2
Show member pathways
12.72 MSH6 MLH1 CTNNB1 CDH1 CASP3 BAX
3
Show member pathways
12.64 MLH1 CTNNB1 CDH1 BAX APC ABCB1
4
Show member pathways
12.56 PTGS2 CTNNB1 CDH1 CASP3 BAX APC
5 12.53 PTGS2 MSH6 MLH1 CTNNB1 CDH1 CASP8
6
Show member pathways
12.36 CTNNB1 CDH1 CASP8 CASP3
7
Show member pathways
12.31 CTNNB1 CASP8 CASP3 BAX
8 12.3 PTGS2 CTNNB1 CDH1 APC
9 11.95 CTNNB1 CDH1 CASP8 CASP3 APC
10
Show member pathways
11.78 CTNNB1 CDH1 CASP8 CASP3 APC
11 11.78 PTGS2 MSH6 MLH1 CTNNB1 CDH1 CASP3
12 11.74 PTGS2 CASP3 BAX
13
Show member pathways
11.67 CASP8 CASP3 BAX
14
Show member pathways
11.66 CASP8 CASP3 BAX
15 11.62 CTNNB1 CDH1 APC
16 11.52 MSH6 MLH1 CASP8 CASP3 BAX
17 11.46 PTGS2 CTNNB1 CASP3
18 11.41 RAD54L ODC1 MSH6 CTNNB1 CDH1 CASP8
19 11.33 MSH6 CASP8 CASP3 BAX
20 11.01 CASP3 BAX ABCB1
21 10.79 PTGS2 ABCB1
22 10.71 CTNNB1 CDH1
23 10.54 BAX ABCB1

GO Terms for Colon Adenocarcinoma

Cellular components related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adherens junction GO:0005912 9.63 CTNNB1 CDH1 APC
2 beta-catenin destruction complex GO:0030877 9.43 CTNNB1 APC
3 cell periphery GO:0071944 9.43 FUT4 CTNNB1 BAX
4 Wnt signalosome GO:1990909 9.4 CTNNB1 APC
5 mismatch repair complex GO:0032300 9.37 MSH6 MLH1
6 flotillin complex GO:0016600 9.32 CTNNB1 CDH1
7 death-inducing signaling complex GO:0031264 9.16 CASP8 CASP3
8 lateral plasma membrane GO:0016328 9.13 CTNNB1 CDH1 APC
9 catenin complex GO:0016342 8.8 CTNNB1 CDH1 APC

Biological processes related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.85 PTGS2 CTNNB1 CASP3 BAX APC
2 response to toxic substance GO:0009636 9.73 TYMS CDH1 BAX
3 response to organic substance GO:0010033 9.72 PTGS2 CDH1 CASP3
4 response to glucocorticoid GO:0051384 9.71 TYMS PTGS2 CASP3
5 apoptotic signaling pathway GO:0097190 9.7 CASP8 CASP3 BAX
6 positive regulation of neuron apoptotic process GO:0043525 9.67 CTNNB1 CASP3 BAX
7 cellular response to DNA damage stimulus GO:0006974 9.63 RAD54L MSH6 MLH1 CASP3 BAX APC
8 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.61 MSH6 MLH1 BAX
9 entry of bacterium into host cell GO:0035635 9.51 CTNNB1 CDH1
10 response to cobalt ion GO:0032025 9.48 CASP8 CASP3
11 response to tumor necrosis factor GO:0034612 9.43 PTGS2 CASP8 CASP3
12 cellular response to indole-3-methanol GO:0071681 9.4 CTNNB1 CDH1
13 somatic recombination of immunoglobulin gene segments GO:0016447 9.37 MSH6 MLH1
14 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.32 CASP8 BAX
15 response to estradiol GO:0032355 9.26 PTGS2 CTNNB1 CASP8 CASP3
16 response to drug GO:0042493 9.17 TYMS RAD54L PTGS2 CTNNB1 CDH1 CASP3

Molecular functions related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.4 CASP8 CASP3
2 death receptor binding GO:0005123 9.37 CASP8 CASP3
3 gamma-catenin binding GO:0045295 9.32 CDH1 APC
4 mismatched DNA binding GO:0030983 9.26 MSH6 MLH1
5 protein homodimerization activity GO:0042803 9.23 TYMS ST6GAL1 PTGS2 ODC1 MSH6 CEACAM5
6 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 9.16 CASP8 CASP3
7 guanine/thymine mispair binding GO:0032137 8.96 MSH6 MLH1

Sources for Colon Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....